Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02435342 | A 4 Week Study of the Safety, Tolerability, and Pharmacodynamics of ShK-186 (Dalazatide) in Active Plaque Psoriasis | PHASE1 | COMPLETED | 24 | — | — | Oct 1, 2014 | Mar 1, 2015 | May 6, 2015 | 1 | Canada |
| Arm | Type | Description |
|---|---|---|
| 30ug dalazatide | EXPERIMENTAL | 12 subjects, 10 given active agent and 2 given placebo by subcutaneous injection twice weekly for 4 weeks. |
| 60ug dalazatide | EXPERIMENTAL | 12 subjects, 10 given active agent and 2 given placebo by subcutaneous injection twice weekly for 4 weeks. |
| Name | Type | Description |
|---|---|---|
| dalazatide | DRUG | Subcutaneous injection twice per week for a total of 9 doses, followed by four weeks of follow-up. |
| placebo | DRUG | placebo, Subcutaneous injection twice per week for a total of 9 doses |
Inclusion Criteria: 1. Adult male and female subjects, ages 18-65; 2. Active plaque psoriasis with ≥3% BSA involved; 3. An adequate number of vulgar psoriatic plaques of at least 2 cm X 2 cm with Target Lesion Investigator Global Assessment scores \>3, that are not located on the face, scalp, groin...